Anti-α4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model

In a syngeneic murine model of multiple myeloma with many of the characteristics of the human disease, a monoclonal antibody (mAb) to the integrin very late antigen-4 (VLA-4), given after the myeloma has already homed to and begun to establish itself within the bone marrow compartment, produces stat...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cancer therapeutics 2005-01, Vol.4 (1), p.91-99
Main Authors: Olson, Dian L., Burkly, Linda C., Leone, Diane R., Dolinski, Brian M., Lobb, Roy R.
Format: Article
Language:English
Subjects:
integrin
monoclonal antibody
Myeloma
VLA-4
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a syngeneic murine model of multiple myeloma with many of the characteristics of the human disease, a monoclonal antibody (mAb) to the integrin very late antigen-4 (VLA-4), given after the myeloma has already homed to and begun to establish itself within the bone marrow compartment, produces statistically significant effects on multiple disease variables. These include reductions in circulating levels of IgG2b; percentage of IgG2b-positive myeloma cells circulating in blood; spleen weight; and myeloma cell burden in spleen, bone marrow, and liver. mAb therapy had no effect on nonmalignant hematopoietic cells. An acute 6-day regimen of mAb treatment, initiated very late in disease to avoid mAb elimination in the immunocompetent animals, still significantly reduced spleen and blood myeloma cell burden. The ability of the (VLA-4) mAb to affect multiple variables in this model, even as monotherapy, suggests this pathway plays a central role in disease progression.
ISSN:1535-7163
1538-8514
DOI:10.1158/1535-7163.91.4.1